Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 20, 2020 - Issue 4: Ulcerative Colitis
Submit an article Journal homepage
167
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Epidemiological data and utilization patterns of anti-TNF alpha therapy in the Hungarian ulcerative colitis population between 2012-2016

Péter KunovszkiJanssen Pharmaceutica NV, Budapest, HungaryView further author information
,
Kata Judit SzántóFirst Department of Medicine, University of Szeged, Szeged, HungaryORCID Iconhttps://orcid.org/0000-0003-0749-5061View further author information
ORCID Icon,
Judit Gimesi-OrszághJanssen Pharmaceutica NV, Budapest, HungaryView further author information
,
Péter TakácsJanssen Pharmaceutica NV, Budapest, HungaryView further author information
,
András BorsiJanssen-Cilag Limited, High Wycombe, UKORCID Iconhttps://orcid.org/0000-0003-4612-9830View further author information
ORCID Icon,
Anita BálintFirst Department of Medicine, University of Szeged, Szeged, HungaryORCID Iconhttps://orcid.org/0000-0002-3624-896XView further author information
ORCID Icon,
Klaudia FarkasFirst Department of Medicine, University of Szeged, Szeged, HungaryORCID Iconhttps://orcid.org/0000-0003-0599-182XView further author information
ORCID Icon,
Ágnes MilassinFirst Department of Medicine, University of Szeged, Szeged, HungaryORCID Iconhttps://orcid.org/0000-0001-6902-8915View further author information
ORCID Icon,
Péter L. LakatosDepartment of Medicine, Semmelweis University, Budapest, Hungary;Division of Gastroenterology, McGill University, Montreal, CanadaView further author information
,
Tamás SzamosiDepartment of Gastroenterology, Military Hospital-State Health Centre, Budapest, HungaryView further author information
&
Tamás MolnárFirst Department of Medicine, University of Szeged, Szeged, HungaryCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4913-7599View further author information
ORCID Icon show all
Pages 443-449 | Received 06 Aug 2019, Accepted 15 Jan 2020, Published online: 28 Jan 2020

References

  • Végh Z, Kürti Z, Lakatos PL. Epidemiology of inflammatory bowel diseases from west to east. J Dig Dis. 2017;18(2):92.
  • Ghione S, Sarter H, Fumery M, et al. Dramatic increase in incidence of ulcerative Colitis and Crohn’s disease (1988–2011): a population-based study of French adolescents. Am J Gastroenterol. 2018;113(2):265–272.
  • Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322−37.
  • Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroent. 2015;50(8):942–951.
  • Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778.
  • Rencz F, Péntek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol. 2015;21(6):1728–1737.
  • Targownik LE, Tenakaroon A, Leung S, et al. Temporal trends in anti-TNF initiation among persons with IBD: a population based analysis. Clin Gastroenterol Hepatol. 2017;15:1061–1070.
  • Larsen L, Drewes AM, Broberg MCH, et al. Changing infliximab prescription patterns in inflammatory bowel disease: a population-based cohort study, 1999–2014. Inflamm Bowel Dis. 2018 Jan 18;24(2):433–439. .
  • Farkas K, Lakatos PL, Nagy F, et al. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol. 2013 Dec;48(12):1394–1398.
  • Molnár T, Lakatos PL, Farkas K, et al. Predictors of relapse in patients with Crohn’s disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther. 2013 Jan;37(2):225–233. .
  • Kane SV, Jaganathan S, Bedenbaugh AV, et al. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn’s disease. Curr Med Res Opin. 2014;30(9):1821–1826.
  • Taxonera C, Iglesias E, Muñoz F, et al. Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation. Dig Dis Sci. 2017;62(2):481–490.
  • Sandborn WJ, Sakuraba A, Wang A, et al. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016;32(7):1233–1241.
  • Black CM, Yu E, McCann E, et al. Dose escalation and healthcare resource use among ulcerative colitis patients treated with adalimumab in english hospitals: an analysis of real-world data. PLoS ONE. 2016;11:2.
  • Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. DOI:10.1136/gutjnl-2013-305279.
  • Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol. 2018;11:1756283X17745029.
  • Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.